Market Cap : 229.24 M | Enterprise Value : 154.88 M | PE Ratio : At Loss | PB Ratio : 2.89 |
---|
NAS:VTGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:VTGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
VistaGen Therapeutics's net current asset value per share for the quarter that ended in Dec. 2021 was $0.37.
The historical rank and industry rank for VistaGen Therapeutics's Net Current Asset Value or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of VistaGen Therapeutics was 65.33. The lowest was 2.52. And the median was 7.33.
VTGN's Price-to-Net-Current-Asset-Value is ranked better thanThe historical data trend for VistaGen Therapeutics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, VistaGen Therapeutics's Net Current Asset Value, along with its competitors' market caps and Net Current Asset Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's Net Current Asset Value distribution charts can be found below:
* The bar in red indicates where VistaGen Therapeutics's Net Current Asset Value falls into.
VistaGen Therapeutics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Mar. 2021 is calculated as
Net Current Asset Value Per Share | (A: Mar. 2021 ) | ||||||||
= | (Total Current Assets | - | Total Liabilities | - | Minority Interest | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (104.118 | - | 16.303 | - | 0 | - | 0.004) | / | 180.616 |
= | 0.49 |
VistaGen Therapeutics's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2021 is calculated as
Net Current Asset Value Per Share | (Q: Dec. 2021 ) | ||||||||
= | (Total Current Assets | - | Total Liabilities | - | Minority Interest | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (86.77 | - | 10.558 | - | 0 | - | 0) | / | 206.509 |
= | 0.37 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of GrahamÂ’s strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener. GuruFocus also publishes a monthly Net-Net newsletter.
Thank you for viewing the detailed overview of VistaGen Therapeutics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Saxe Jon S | director | FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076 |
Dotson Jerrold Duane | officer: VP, CFO AND SECRETARY | 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035 |
Singh Shawn | director, officer: CHIEF EXECUTIVE OFFICER | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Snodgrass H. Ralph | director, officer: PRES./CHIEF SCIENTIFIC OFFICER | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Smith Mark Alan | officer: CHIEF MEDICAL OFFICER | 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Mcpartland Mark A. | officer: VP CORPORATE DEVELOPMENT | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Gin Jerry B | director | 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080 |
Underdown Brian J. | director | C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000 |
Cunningham Ann Michelle | director | 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335 |
Rice A. Franklin | officer: VP CORPORATE DEVELOPMENT | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Bonfiglio Gregory A. | director | 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080 |
Platinum Long Term Growth Vii, Llc | 10 percent owner | 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 |
Cato Holding Co | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Cato Allen Easley | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Jones Stephanie | director, 10 percent owner, officer: PRESIDENT | 13834 W. HOYT ROAD RATHDRUM ID 83858 |
From GuruFocus
Other Sources
By Fool 2021-06-30
By tipranks.com 2022-03-03
By tipranks.com 2022-02-13
By Seekingalpha 2022-02-10
By Zacks 2021-03-11
By Seekingalpha 2021-06-29
By Zacks 2021-02-11
By Zacks 2021-10-20
By Zacks 2021-11-10
By Zacks 2022-04-05
By Seekingalpha 2021-01-24
By Seekingalpha 2021-11-10
By Zacks 2021-06-16
By Zacks 2021-08-12